TH1L (also known as NELF‐C/D) is a member of the Negative Elongation Factor (NELF) complex, which is a metazoan‐specific factor that regulates RNA Polymerase II (RNAPII) pausing and transcription elongation. However, the function and molecular mechanisms of TH1L in cancer progression are still largely unknown. In this study, we found that TH1L was highly expressed in colorectal cancer (CRC) tissues and the faeces of CRC patients. Overexpression of TH1L significantly enhanced the proliferation and migration of CRC cells, while its knockdown markedly suppressed these processes. In mechanism, RNA sequencing revealed that CCL20 was upregulated in TH1L‐overexpressed CRC cells, leading to activation of the NF‐κB signalling pathway. Rescue assays showed that knockdown of CCL20 could impair the tumour‐promoting effects of THIL in CRC cells. Taken together, these results suggest that TH1L may play a vital role via the CCL20/NF‐κB signalling pathway in CRC proliferation and migration and may serve as a potential target for diagnosis and therapy of CRC.
Background: The E3 ubiquitin ligase CHIP/STUB1 is a known tumor suppressor in colorectal cancer (CRC) and other malignancies, but its mechanistic role in metabolic reprogramming remains elusive. This study aimed to elucidate whether CHIP regulates glycolysis in CRC through targeting key metabolic enzymes. Methods: Lentiviral systems were employed to generate SW480 and DLD1 cells with stable CHIP overexpression or knockout. These cells were subsequently assessed for proliferation, colony formation, and tumorigenic capacity in subcutaneous xenograft models. Lactate production, LDH activity, ATP levels, and histone lactylation were measured in CRC cells with altered CHIP expression. Mechanistically, Western blot, cycloheximide chase, immunoprecipitation, pull-down, and ubiquitination assays were conducted to dissect the underlying molecular events. Rescue experiments were finally performed both in vivo and in vitro to validate the functional relevance of this regulatory axis in CRC. Results: CHIP overexpression suppressed glycolysis and markedly inhibited CRC proliferation and tumorigenesis in vivo and in vitro. Mechanistically, CHIP directly bound LDHA via its TPR domain and promoted K48-linked polyubiquitination and proteasomal degradation of LDHA. This CHIP-mediated LDHA degradation reduced lactate production and subsequently decreased histone H3 lysine 18 lactylation (H3K18la), leading to transcriptional repression of cell cycle-related genes. Conclusion: This work identifies LDHA as a substrate of CHIP and demonstrates that CHIP acts as a critical negative regulator of the Warburg effect in CRC. The CHIP–LDHA axis thus couples metabolic with epigenetic reprogramming and represents a potential therapeutic target.